JBIO: Jade Biosciences, Inc.
Performance
JBIO +69.75%
Watchlist
Select an item
Summary
JBIO at a glance
JBIO returned +69.75% over the past year. Its worst drop in that year was -50.06%, smaller than 23% of stocks on Redstone, and its Sharpe ratio of 1.04 beats 77% of stocks on Redstone. It pays no dividends.
Current Drawdown
-41.90%
Rolling Volatility
54.31%
Actions
Metrics
Risk Indicators
Alpha62.53%
Beta1.26x
Sharpe1.04
Sortino1.64
Omega1.20
Calmar1.39
Martin3.05
Profile
About JBIO
Jade Biosciences Inc is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases. Its flagship candidate, JADE101, targets the cytokine APRIL and is in a Phase 1 clinical trial for the treatment of immunoglobulin A nephropathy.
- Sector
- Health Care
- Industry
- Pharmaceutical Preparations
- Market cap
- $992M
- Listed
- Apr 2025
- Employees
- 55
- Headquarters
- Waltham, MA
- Website
- jadebiosciences.com
Comparisons